SAB Biotherapeutics

SABS

時価総額 $2.3億

MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference: Date: October 20, 2026Time: 11:15 - 11:30 a.m. ETFormat: Fireside Chat Presenter: Samuel J.

Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes

MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 - October 2, 2026 in Milan, Italy. Presented data will highlight SAB BIO's lead program, SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:

SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE ‑ hATG study of SAB ‑ 142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis Operational runway through 2028 to support SAFEGUARD study, PRISE-hATG study and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and provided business highlights. “The second quarter was marked by strong execution as we advanced SAB-142 across key clinical and operational milestones.

MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who are 100 days to 2 years from diagnosis. Stage 3 T1D is diagnosed when the disease has progressed to a point where insulin is required.

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D